Aytu BioScience

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Aytu BioScience reports robust Q3 performance, eyes growth through innovation

Aytu BioScience delivered strong financial results in Q3 2024, with notable revenue and margin improvements. The company's strategic focus on specialty pharmaceuticals and operational efficiency bodes well for future growth. While challenges like supply chain disruptions exist, Aytu is poised for continued success through innovation and market opportunities.

Aytu BioScience reports robust earnings, focuses on growth strategies

Aytu BioScience demonstrated strong financial performance with improved EBITDA and strategic repositioning
While facing challenges in certain portfolio revenues, the company is focused on growth opportunities
Strategic initiatives like the RxConnect program and product expansion are key strengths
Addressing market challenges and seizing growth opportunities will be crucial for future success

Aytu BioPharma reports first-ever positive net income in Q1 2025

Aytu BioPharma delivered a strong performance in Q1 2025, achieving positive net income, sustained profitability, and operational efficiency amidst market challenges.
The company's focus on optimizing operations, reducing expenses, and pursuing growth opportunities positions it well for future revenue expansion and market competitiveness.
While facing challenges in a dynamic market environment, Aytu BioPharma has opportunities to leverage its strengths in key portfolios and strategic initiatives for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on September 27, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the fourth quarter and fiscal year 2021 and provide an overview of its business and growth strategy.

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23 rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m.

Aytu BioPharma to Present at Upcoming September Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the Healight™ endotracheal catheter technology was published in the peer reviewed journal Photodiagnosis and Photodynamics Therapy. "These latest in vitro findings continue to build upon the body of scientific evidence supporting the potential of this UVA platform technology and may help to explain the observed effects of Healight in SARS-CoV-2.

Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus

Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.

Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options

Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients ENGLEWOOD, CO / ACCESSWIRE / June 28, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A (UVA) light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy. The UVA light catheter technology utilized in this study is the basis of Aytu BioPharma's Healight™ medical device which has been exclusively licensed worldwide for all endotracheal and nasopharyngeal applications.

Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study

Aytu BioPharma Inc. (NASDAQ: AYTU) shares were rallying Monday after retail traders were able to push the stock higher. The stock has traded on above-average volume with 7.6 million shares traded so far — over 1,000% its average volume over the last 100 days.

Technical Levels To Watch In Aytu BioPharma Stock

Aytu BioPharma Inc. (NASDAQ: AYTU) shares saw a gap up Tuesday morning as retail traders tried to push the stock higher. The stock saw a sizable premarket move and opened at $6.15, but has since fallen back near the $5.70 price level.

What's Next For Aytu BioPharma Stock As It Gaps Up To Resistance?

ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies Global Healthcare Conference: A live virtual presentation will occur on Tuesday, June 1, 2021 at 3:30 p.m. ET. Webcast Link: https://wsw.com/webcast/jeff174/aytu/1881765 Raymond James Human Health Innovations Conference: A live virtual presentation will occur on Wednesday, June 23, 2021 at 12:40 p.m.

Aytu BioPharma to Present at Upcoming June Investor Conferences

Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript

Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to ($0.43), which missed the estimate of ($0.31).

Recap: Aytu BioPharma Q3 Earnings

- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline - - Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year - - Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET - ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights.

Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used in the Healight™ UVA endotracheal catheter technology was published in BioRxiv, an online archive for health science manuscripts that are not yet peer reviewed. The manuscript titled "Ultraviolet-A light increases mitochondrial anti-viral signaling protein via cell-cell communication" concluded that UVA light increases the expression of mitochondrial antiviral-signaling (MAVS) protein within cells, and the results suggest that this transmission of an increase in intracellular MAVS involves cell-to-cell communication.

Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells

ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.

Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline Company to host conference call today at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) from Rumpus Therapeutics (Rumpus), a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases. vEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus.

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Amtech Systems

Avid Bioservices

Interactive Brokers

Oncternal Therapeutics Inc

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

5 Stocks to Buy on New Analyst Coverage

ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations, supporting clinical development and commercialization, and raising capital within the life sciences sector.

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer

Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation (ASP)(ASPCF) whereby Acerus will acquire all remaining rights to Natesto in the United States from Aytu. In consideration, Aytu will receive $7.5M in cash from Acerus, which is payable in $250,000 monthly payments over 30 months.

Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

Bionano Genomics

Citius Pharmaceuticals

Denison Mines

Hall of Fame Resort & Entertainment

Ideanomics Inc

Marker Therapeutics Inc

Neos Therapeutics

Zomedica

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

10 Reddit Penny Stocks Seeing the Most Chatter Today

$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth P. Hecht and Gerald McLaughlin have joined the Aytu BioPharma board of directors ENGLEWOOD, CO / ACCESSWIRE / March 22, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the closing of its merger with Neos Therapeutics (previously trading on Nasdaq under "NEOS").

Aytu BioScience Announces Close of Merger with Neos Therapeutics

Aytu Biosciences Inc. (NASDAQ: AYTU) shares gapped up Thursday morning. The price jump is speculatively from the meetings the company is having about the proposed merger with Neos Therapeutics Inc. (NASDAQ: NEOS).

Why Did Aytu Biosciences Gap Up Today? Technical Levels To Watch

NEOS stock holders will get AYTU stock in this no-cash merger transaction. Today's vote has the support of two proxy advisory firms.

Merger News: Why NEOS Stock and AYTU Stock Are Climbing Today

Neos Therapeutics Inc (NASDAQ: NEOS) and Aytu BioScience Inc (NASDAQ: AYTU) shares are rising today in the premarket session, though there is no news on both companies. The investors are reacting to the companies' respective special meetings of stockholders related to the proposed merger between Aytu and Neos that will happen today.

Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?

Initial details from the FDA-approved trial for the Healight medical device published by Cedars-Sinai show that UVA therapy may be a safe and effective treatment for severe SARS-CoV-2 infection. Cedars-Sinai and Aytu BioScience are working with the FDA to confirm the next steps on the advancement of this technology, including a more comprehensive trial and possibly an Emergency Use Authorization.

Aytu BioScience: The Moonshot Continues To Orbit Awaiting The Next Giant Steps

Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?

Aytu BioScience Inc (NASDAQ: AYTU) rises sharply in the premarket after first-in-human data with endotracheal UVA light catheter therapy show positive outcome in SARS-CoV-2 patients.  Known as Healight, light catheter therapy is an investigational medical device being studied as a prospective treatment for COVID-19 and other respiratory infections.

News for Aytu BioScience Stock (AYTU)